Bridgeway Capital Management LLC Trims Stock Holdings in Nektar Therapeutics (NASDAQ:NKTR)

Bridgeway Capital Management LLC lessened its stake in shares of Nektar Therapeutics (NASDAQ:NKTR) by 5.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,292,100 shares of the biopharmaceutical company’s stock after selling 70,000 shares during the quarter. Bridgeway Capital Management LLC owned approximately 0.70% of Nektar Therapeutics worth $1,202,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets grew its holdings in shares of Nektar Therapeutics by 30.9% during the fourth quarter. BNP Paribas Financial Markets now owns 312,693 shares of the biopharmaceutical company’s stock worth $291,000 after buying an additional 73,847 shares in the last quarter. Ameriprise Financial Inc. grew its stake in Nektar Therapeutics by 32.8% in the 4th quarter. Ameriprise Financial Inc. now owns 373,948 shares of the biopharmaceutical company’s stock worth $348,000 after acquiring an additional 92,346 shares during the period. 22NW LP acquired a new position in Nektar Therapeutics in the 4th quarter valued at $2,038,000. Nantahala Capital Management LLC lifted its stake in shares of Nektar Therapeutics by 90.0% during the 4th quarter. Nantahala Capital Management LLC now owns 7,810,000 shares of the biopharmaceutical company’s stock worth $7,263,000 after purchasing an additional 3,700,000 shares during the period. Finally, Northern Trust Corp boosted its holdings in shares of Nektar Therapeutics by 0.9% during the fourth quarter. Northern Trust Corp now owns 1,414,984 shares of the biopharmaceutical company’s stock worth $1,316,000 after purchasing an additional 12,826 shares during the last quarter. Institutional investors and hedge funds own 75.88% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on the company. William Blair reiterated a “market perform” rating on shares of Nektar Therapeutics in a research note on Thursday, March 13th. StockNews.com initiated coverage on shares of Nektar Therapeutics in a research report on Wednesday, April 16th. They issued a “hold” rating on the stock. Oppenheimer raised shares of Nektar Therapeutics from a “market perform” rating to an “outperform” rating and set a $6.00 price target for the company in a research report on Friday, March 14th. Jefferies Financial Group upgraded shares of Nektar Therapeutics from a “hold” rating to a “buy” rating and lifted their price target for the company from $1.00 to $2.00 in a report on Friday, April 11th. Finally, HC Wainwright restated a “buy” rating and set a $6.50 price objective on shares of Nektar Therapeutics in a report on Thursday, March 13th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $4.50.

Nektar Therapeutics Trading Down 4.9 %

NASDAQ:NKTR opened at $0.59 on Friday. The firm’s fifty day simple moving average is $0.71 and its 200 day simple moving average is $0.90. Nektar Therapeutics has a twelve month low of $0.43 and a twelve month high of $1.93. The firm has a market capitalization of $109.56 million, a price-to-earnings ratio of -0.70 and a beta of 0.62.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.04). Nektar Therapeutics had a negative return on equity of 173.28% and a negative net margin of 180.70%. The company had revenue of $10.46 million for the quarter, compared to analyst estimates of $15.61 million. During the same quarter in the prior year, the firm earned ($0.18) EPS. On average, analysts predict that Nektar Therapeutics will post -0.72 earnings per share for the current year.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.